Clinical trials: Mild Cognitive Impairment
Alzheimer's Disease, Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with…
- Conditions
- Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment
- Trial name
- NCT04445831
- Testing
- ACI-35.030, JACI-35.054
- Where
- 9 sites in Finland, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- AC Immune SA
Alzheimer Disease, Dementia
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT07839286
- Testing
- Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Callahan-Young LLC DBA Jigsawdio
Neurological Diseases or Conditions, Dementia of Alzheimer Type
An Observational Study of Patients Living With Chronic Neurological Diseases
TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment…
- Conditions
- Neurological Diseases or Conditions, Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT05796037
- Volunteers
- 1,500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Mild Cognitive Impairment
Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS
The goal of the proposed observational, multi-site study is to use fNIRS neurophysiological data recorded during a battery of tasks to detect MCI within a cohort consisting of patients and age-matched healthy controls.
- Trial name
- IMPACT (NCT05996575)
- Testing
- fNIRS measurement
- Where
- 6 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Kernel
Alzheimer's Disease, Mild Cognitive Impairment
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
This study will evaluate the safety, tolerability, and pharmacokinetics of MK-4334 administered once daily (QD) in participants with Alzheimer's clinical syndrome receiving a stable, daily dose of donepezil 10 mg, taken orally…
- Trial name
- NCT03740178
- Testing
- MK-4334, Donepepzil
- Sponsor
- Merck Sharp & Dohme LLC
Mild Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Effect of AQW051 in Patients With Memory Impairment
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure…
- Trial name
- NCT00582855
- Testing
- AQW051
- Where
- 12 sites in Canada, South Africa and 1 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Disorder
Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions
Safety and performance study of the MemoWave electroencephalographic and sound recording device to increase slow brain waves during sleep to improve memory consolidation in subjects with mild cognitive impairment
- Trial name
- MEMOWAVE (NCT04875442)
- Testing
- Memowave emitting sounds, Memowave not emitting sounds
- Where
- France
- Sponsor
- BioSerenity
Alzheimer Disease, Chronic Traumatic Encephalopathy
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected…
- Trial name
- NCT06254469
- Testing
- [F-18]Flornaptitril
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- CereMark Pharma, LLC
Healthy Volunteers
A Study of LY2886721 in Healthy Participants
The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the…
- Trial name
- NCT01534273
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Mild Cognitive Impairment
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.
- Trial name
- NCT05041790
- Testing
- Choline Alfoscerate
- Where
- South Korea
- Volunteers
- 418 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands Observing Progression With Neurons Study
The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
- Trial name
- CROWN-I (NCT07611396)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Crownlands
Mild Cognitive Impairment
Multidisciplinary Intervention for Mild Cognitive Impairment
The purpose of this investigation is to conduct a series of case studies on the impact of a novel functional medicine approach to improving cognitive skills, brain structure, and daily functioning for participants with Mild…
- Trial name
- (MCI) (NCT02943187)
- Testing
- Cognitive training, Nutrition
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Gibson Institute of Cognitive Research
Mild Cognitive Impairment, Alzheimer's Disease(AD)
Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease
This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and…
- Trial name
- NCT07239310
- Testing
- Participants receive Neuclare Device while continuing their cognitive medication
- Where
- 7 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- Deepsonbio
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
- Trial name
- NCT02211560
- Testing
- Phosphatidylserine
- Where
- 15 sites in United States, Israel
- Volunteers
- 97 people
- Sponsor
- Enzymotec
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
- Trial name
- NCT01421056
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 6 sites in United States, Italy
- Volunteers
- 74 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cognitive Impairment, Alzheimer Disease
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
The clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions.
- Trial name
- MemScreen (NCT03811184)
- Testing
- MemScreen
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MemScreen
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT04141150
- Testing
- [18F]APN-1607
- Where
- 3 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC